Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

5

US Approved OTC

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

C55-isoprenyl pyrophosphate

5

Apoptosis

4

Oxidative Stress

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

9

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

5

1987

4

2010

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Infection

5

Skin diseases

5

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

5

Blood Transfusion

4

Coronary Disease

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

5

Inactive ingredient

4

Palliative

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Goorley, J.T.

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

Mixture

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

10

CAS

9

DAILYMED

8

ECHA (EC/EINECS)

8

EPA CompTox

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

2

ANTIINFECTIVES FOR SYSTEMIC USE

1

CARDIOVASCULAR SYSTEM

1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

1

MEDICATED DRESSINGS

1

OPHTHALMOLOGICALS

1

THROAT PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

1

ANTIBIOTICS FOR TOPICAL USE

1

ANTIINFECTIVES

1

MEDICATED DRESSINGS

1

OTHER ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antibiotics

1

Other agents for treatment of hemorrhoids and anal fissures for topical use

1

Other antibacterials

1

Other antibiotics for topical use

1

Other antiinfectives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ANISYL ALCOHOL

7N6XGV3U49

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1984

Class (Stereo):

CHEMICAL (ACHIRAL)

PYRUVIC ACID

8558G7RUTR

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Oxidative Stress

Conditions:

Blood Transfusion

Coronary Disease

CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scave...

nger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.

Bacitracin

58H6RWO52I

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

ZINC

J41CSQ7QDS

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

PYRUVATE ION

HO43T60JMG

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Oxidative Stress

Conditions:

Blood Transfusion

Coronary Disease

CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scave...

nger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.

ETHYL PYRUVATE

03O98E01OB

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Oxidative Stress

Conditions:

Blood Transfusion

Coronary Disease

CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scave...

nger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.

SODIUM PYRUVATE

POD38AIF08

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Oxidative Stress

Conditions:

Blood Transfusion

Coronary Disease

CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scave...

nger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.

BACITRACIN METHYLENEDISALICYLATE SODIUM

1EJ7TZQ03Q

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

BACITRACIN METHYLENEDISALICYLATE

JGV6OJ52FT

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

BACITRACIN ZINC

89Y4M234ES

Status:

US Approved OTC

First marketed in 1921

Class:

MIXTURE

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1